Scaling up Health Services for Type 1 Diabetes in India, 2023

Scaling up Health Services for Type 1 Diabetes in India, 2023

This report, “Scaling up Health Services for Type 1 Diabetes in India: Towards a strategy to transition to sustainability of programmes supported by CDIC in India ”, was developed under the guidance of Professor Rifat Atun, Professor of Global Health Systems at Harvard University and Director of the Health Systems Innovation Lab. The study was supported by Novo Nordisk financially supported this work through a research grant. The funders had no role in study design, analysis, decision to publish, or report preparation.

Edition 40 –  The Evolution of WHIMS – What Healthcare Organizations Can Learn from Its Genesis, Development, and Future Potential 

Edition 40 –  The Evolution of WHIMS - What Healthcare Organizations Can Learn from Its Genesis, Development, and Future Potential 

 The Evolution of WHIMS – What Healthcare Organizations can learn from its genesis, development, and future potential By Dr Nadeem Ahmed, Gabriel Oke Share on facebook Facebook Share on twitter Twitter Share on linkedin LinkedIn Citation Ahmed N and Oke G. The evolution of WHIMS – What healthcare organizations can learn from its genesis, development, […]

Strategic Public-Private Partnerships to Transform Cardiovascular Health, 2022

Strategic Public Private Partnerships to Transform Cardiovascular Health.png

The study, Strategic Public-Private Partnerships to Transform Cardiovascular Health, was developed under the guidance of Professor Rifat Atun, Professor of Global Health Systems at Harvard University and Director of the Health Systems Innovation Lab and implemented by the Health Systems Innovation Lab at Harvard University.

State of Cardiovascular Disease in G20+ Countries

Appendix State Of Cardiovascular Disease In G20+ Countries appendix

This study was developed under the guidance of Professor Rifat Atun, Professor of Global Health Systems at the Harvard Chan School, Harvard University and Director of the Health Systems Innovation Lab, and Francesca Colombo, Head of the Health Division at the Organization for Economic Cooperation and Development (OECD) and implemented by a team of researchers and contributors from the Health Systems Innovation Lab (HSIL) at Harvard University and the OECD.

Appendix: Cardiovascular Disease in G20+ Countries

Appendix State Of Cardiovascular Disease In G20+ Countries appendix

This is the appendix for the report, developed under the guidance of Professor Rifat Atun, Professor of Global Health Systems at the Harvard Chan School, Harvard University and Director of the Health Systems Innovation Lab, and Francesca Colombo, Head of the Health Division at the Organization for Economic Cooperation and Development (OECD) and implemented by a team of researchers and contributors from the Health Systems Innovation Lab (HSIL) at Harvard University and the OECD.

Edition 40 – Are We Ready for Telerehabilitation to Become Mainstream? Opinion About Upper Extremity Orthopedic Conditions

Edition 40 – Are We Ready for Telerehabilitation to Become Mainstream? Opinion About Upper Extremity Orthopedic Conditions

Are We Ready for Telerehabilitation to Become Mainstream? Opinion About Upper Extremity Orthopedic Conditions By Thierry Lienou, OTD, OTR/L, CAPS, ATP Facebook Twitter LinkedIn Citation Lienou T. Are we reaady for telerehabilitation to become mainstream? Opinion about upper extremity orthopediuc conditions. HPHR. 2021;40.   DOI:10.54111/0001/NN3 Are we ready for telerehabilitation to become mainstream? Opinion about […]

Edition 40 – AI to Transform the Drug Approval Process and De-Risk Drug Development

Edition 40 – AI to Transform the Drug Approval Process and De-Risk Drug Development

AI to Transform the Drug Approval Process and De-Risk Drug Development By Cherubin Manokaran Facebook Twitter LinkedIn Citation Manokaran C. AI to transform the drug approval process and de-risk drug development. HPHR. 2021;40. 10.54111/0001/NN4 AI to Transform the Drug Approval Process and De-risk Drug Development Abstract The public tends to view high drug prices through […]